PURPOSE: To compare percutaneous coronary intervention (PCI) using stent implantation versus coronary artery bypass graft (CABG) in patients with multiple vessel disease with involvement of the proximal left anterior descending coronary artery (LAD). METHODS:230 patients with multiple vessel disease and severe stenosis of the proximal LAD (113 with PCI, 117 with CABG). They were a cohort of patients from the randomised ERACI (Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgeryin multivessel disease) II study. RESULTS: Both groups had similar baseline characteristics. There were no significant differences in 30 day major adverse cardiac events (death, myocardial infarction, stroke, and repeat procedures) between the strategies (PCI 2.7% v CABG 7.6%, p = 0.18). There were no significant differences in survival (PCI 96.4% v CABG 95%, p = 0.98) and survival with freedom from myocardial infarction (PCI 92% v CABG 89%, p = 0.94) at 41.5 (6) months' follow up. However, freedom from new revascularisation procedures (CABG 96.6% v PCI 73%, p = 0.0002) and frequency of angina (CABG 9.4% v PCI 22%, p = 0.025) were superior in the CABG group. CONCLUSION:Patients with multivessel disease and significant disease of the proximal LAD randomly assigned in the ERACI II trial toPCI or CABG had similar survival and survival with freedom from myocardial infarction at long term follow up. Repeat revascularisation procedures were higher in the PCI group.
RCT Entities:
PURPOSE: To compare percutaneous coronary intervention (PCI) using stent implantation versus coronary artery bypass graft (CABG) in patients with multiple vessel disease with involvement of the proximal left anterior descending coronary artery (LAD). METHODS: 230 patients with multiple vessel disease and severe stenosis of the proximal LAD (113 with PCI, 117 with CABG). They were a cohort of patients from the randomised ERACI (Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease) II study. RESULTS: Both groups had similar baseline characteristics. There were no significant differences in 30 day major adverse cardiac events (death, myocardial infarction, stroke, and repeat procedures) between the strategies (PCI 2.7% v CABG 7.6%, p = 0.18). There were no significant differences in survival (PCI 96.4% v CABG 95%, p = 0.98) and survival with freedom from myocardial infarction (PCI 92% v CABG 89%, p = 0.94) at 41.5 (6) months' follow up. However, freedom from new revascularisation procedures (CABG 96.6% v PCI 73%, p = 0.0002) and frequency of angina (CABG 9.4% v PCI 22%, p = 0.025) were superior in the CABG group. CONCLUSION:Patients with multivessel disease and significant disease of the proximal LAD randomly assigned in the ERACI II trial to PCI or CABG had similar survival and survival with freedom from myocardial infarction at long term follow up. Repeat revascularisation procedures were higher in the PCI group.
Authors: K A Eagle; R A Guyton; R Davidoff; G A Ewy; J Fonger; T J Gardner; J P Gott; H C Herrmann; R A Marlow; W C Nugent; G T O'Connor; T A Orszulak; R E Rieselbach; W L Winters; S Yusuf; R J Gibbons; J S Alpert; K A Eagle; A Garson; G Gregoratos; R O Russell; S C Smith Journal: J Am Coll Cardiol Date: 1999-10 Impact factor: 24.094
Authors: R H Jones; E L Hannan; K E Hammermeister; E R Delong; G T O'Connor; R V Luepker; V Parsonnet; D B Pryor Journal: J Am Coll Cardiol Date: 1996-11-15 Impact factor: 24.094
Authors: T G Hennessy; M B Codd; S Donnelly; C Hartigan; H A McCann; C McCarthy; M Neligan; A E Wood; D Luke; E McGovern; T Aherne; D D Sugrue Journal: Eur Heart J Date: 1998-03 Impact factor: 29.983
Authors: R H Jones; K Kesler; H R Phillips; D B Mark; P K Smith; C L Nelson; M F Newman; J G Reves; R W Anderson; R M Califf Journal: J Thorac Cardiovasc Surg Date: 1996-05 Impact factor: 5.209
Authors: J A Magovern; T Sakert; G J Magovern; D H Benckart; J A Burkholder; G A Liebler; G J Magovern Journal: J Am Coll Cardiol Date: 1996-11-01 Impact factor: 24.094
Authors: S J Pocock; R A Henderson; A F Rickards; J R Hampton; S B King; C W Hamm; J Puel; W Hueb; J J Goy; A Rodriguez Journal: Lancet Date: 1995-11-04 Impact factor: 79.321
Authors: A Rodríguez; F Ayala; V Bernardi; O Santaera; E Marchand; C Pardiñas; C Mauvecin; D Vogel; L C Harrell; I F Palacios Journal: J Am Coll Cardiol Date: 1998-11 Impact factor: 24.094
Authors: A Rodríguez; V Bernardi; M Fernández; C Mauvecín; F Ayala; O Santaera; J Martínez; E Mele; G S Roubin; I Palacios; J A Ambrose Journal: Am J Cardiol Date: 1998-06-01 Impact factor: 2.778
Authors: A A Khattab; C W Hamm; J Senges; R Toelg; V Geist; T Bonzel; M Kelm; B Levenson; C A Nienaber; G Sabin; S Schneider; U Tebbe; G Richardt Journal: Z Kardiol Date: 2005-03
Authors: Immaculate F Nevis; Anna Mathew; Richard J Novick; Chirag R Parikh; Philip J Devereaux; Madhu K Natarajan; Arthur V Iansavichus; Meaghan S Cuerden; Amit X Garg Journal: Clin J Am Soc Nephrol Date: 2009-02 Impact factor: 8.237
Authors: Sandra Eifert; Helmut Mair; Anne-Laure Boulesteix; Eckehard Kilian; Martin Adamczak; Bruno Reichart; Peter Lamm Journal: Vasc Health Risk Manag Date: 2010-08-09
Authors: Mohammad Alidoosti; Mojtaba Salarifar; Ali Mohammad Haji Zeinali; Seyed Ebrahim Kassaian; Maria Raissi Dehkordi Journal: BMC Cardiovasc Disord Date: 2007-03-04 Impact factor: 2.298